SecBot SecBot
SECBOTREPLAY Home › Report › VERA

VERA · Vera Therapeutics reported Q1 2026 results with a net loss of $1.69 per…

Vera Therapeutics, Inc. · 8-K filed May 7, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 4/10

8-K filed May 7, 2026 at 07:30 ET

Vera Therapeutics reported Q1 2026 results with a net loss of $1.69 per share, wider than the $0.81 loss in Q1 2025, driven by increased R&D and G&A spending ahead of a potential atacicept launch. The company maintains a strong cash position of $596.8M and is on track for a mid-2026 U.S. commercial launch pending FDA approval by July 7, 2026.

  • Net loss per diluted share of $1.69 for Q1 2026 vs $0.81 in Q1 2025
  • Cash, cash equivalents, and marketable securities of $596.8M as of March 31, 2026
  • FDA PDUFA target action date for atacicept BLA is July 7, 2026
  • Company expects U.S. commercial launch of atacicept in mid-2026, pending approval

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access